Compare · AIXC vs NVO
AIXC vs NVO
Side-by-side comparison of AIxCrypto Holdings Inc. (AIXC) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIXC and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $168.79B, about 4817.0x AIXC ($35.0M).
- Over the past year, AIXC is down 64.2% and NVO is down 30.0% - NVO leads by 34.1 points.
- AIXC has been more active in the news (6 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for AIXC).
- Company
- AIxCrypto Holdings Inc.
- Novo Nordisk A/S
- Price
- $1.00-40.18%
- $39.23+2.88%
- Market cap
- $35.0M
- $168.79B
- 1M return
- +29.29%
- -5.98%
- 1Y return
- -64.17%
- -30.04%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 6
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AIXC
- SEC Form 8-K filed by AIxCrypto Holdings Inc.
- AIxCrypto Holdings, Inc. Announces Name Change to FF EAI Robotics Ecosystem Inc. and Ticker Symbol Change to FFR
- FF EAI Robotics Ecosystem Inc. (f/k/a AIxCrypto Holdings, Inc.) to Acquire FF Robotics Business for Standalone Listing; Faraday Future Unveils New Execution Plans for "Built In USA" Acceleration Program and Initiates Conditional Approval Application, Will Roll Out New Robot Product in Q1 2027
- AIxCrypto Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- AIxCrypto Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- AIxCrypto Holdings (NASDAQ: AIXC soon to be traded under FFR), Signs Term Sheet with Faraday Future to Acquire its Robotics Business at an Estimated $200 Million Valuation, Aiming to be the First Nasdaq-Listed Pure-Play Robotics Ecosystem Company
- AIxC's RoboShare Advances U.S. Partner Network Development With Technology Upgrades and Standardized Operating Framework
- SEC Form EFFECT filed by AIxCrypto Holdings Inc.
- SEC Form 424B3 filed by AIxCrypto Holdings Inc.
- Amendment: SEC Form S-1/A filed by AIxCrypto Holdings Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank